Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.54 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742454 | 0.88 | HSD11B1 (0.44) | HSD11B1HSD11B2KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3744641 | 0.80 | HSD11B1 (0.47) | HSD11B1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3744663 | 0.80 | HSD11B1 (0.48) | HSD11B1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3752153 | 0.77 | POLB (0.50) | HSD11B1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3747454 | 0.75 | POLB (0.48) | HSD11B1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL12884709 | 0.74 | HSD11B1 (0.57) | HSD11B1HSD11B2SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL1222515 | 0.72 | HSD11B1 (0.55) | HSD11B1HSD11B2 | |
| SCHEMBL4235542 | 0.72 | HSD11B1 (0.55) | HSD11B1HSD11B2 | |
| SCHEMBL3749402 | 0.71 | CYP2D6 (0.43) | HSD11B1KMT2AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL2701428 | 0.71 | KMT2A (0.55) | HSD11B1KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009061681-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061681-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298368-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | HSD11B1 442/4885HSD11B2 264/4885KMT2A 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.